C&L: Bailey exits as Valeant CFO

Valeant Pharmaceuticals said that CFO Bary G. Bailey has resigned. Peter J. Blott, the company's group financial controller, has been named to the position. Bailey will stay with the company through May 31 to assist with the transition.

Idenix announced that David Arkowitz is leaving his position as CFO and treasurer as of March 30 to pursue other opportunities.

Trimeris has announced the departure of Dani Bolognesi, its founder and CEO, and CFO Robert Bonczek.

Dr. Paul D'Sylva has been appointed as a director and CEO of Commonwealth Biotechnologies. His appointment at CBI follows CBI's acquisition of Mimotopes Pty. Ltd. for which Dr. D'Sylva served as managing director and as a member of its board of directors.

David Pendergast, president of Shire Human Genetic Therapies business, is to retire at the end of 2007 and Shire has begun an external search for his replacement.

Allos Therapeutics has named Pablo J. Cagnoni, M.D. as senior vice president, chief medical officer.

Thomas C. Reynolds, M.D., Ph.D., has joined Seattle Genetics as chief medical officer.

Thomas B. Smith, MD, has joined Kendle as global medical director.

Anthera Pharmaceuticals has named James E. Pennington, M.D. to the position of executive Vice president and chief medical officer.

Charles River Laboratories International has named Stephanie Wells to the role of corporate senior vice president, marketing and chief marketing officer.

Tyco Healthcare has named Timothy R. Wright to the position of president of its pharmaceutical products and imaging solutions businesses.

Codexis has named Michael J. Knauf vice president and general manager.

The Burnham Institute for Medical Research has appointed Robert H. Zaugg, Ph.D. to the position of vice president, business development.

Spectrum Pharmaceuticals has added Bela S. Denes, MD, FACS to the ozarelix development team as senior director of clinical research and development.

Pharmatech Associates has named Gregg Ekberg as director of project management.

Outcome Sciences has appointed Kathryn Starzyk as associate director of scientific affairs.

Neostem has hired Arlene Graime as director, government affairs and special projects. Richard Gatti, M.D., a professor at the University of California, Los Angeles, has joined NeoStem's Advisory Board.

Transport Pharmaceuticals has expanded its scientific advisory board with the appointments of Bruce E. Strober, M.D., Ph.D., Agis Kydonieus, Ph.D., and Mark R. Prausnitz, Ph.D. 

Dr. Matthias Grossmann, M.D., Ph.D., and Dr. James Wong, Ph.D., have joined the PAREXEL's International Clinical Pharmacology Network.

Rafick Henein has joined GeoPharma's board of directors. Celsion has elected Dr. Augustine Chow to its board.

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.